Regeneron Pharmaceuticals (REGN.O) on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment, Dupixent.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,